Drug Price Trends for NDC 71288-0404

Average Pharmacy Cost for 71288-0404

Drug Name	NDC	Price/Unit ($)	Unit	Date
HEPARIN SODIUM 10,000 UNIT/ML VIAL	71288-0404-02	2.32424	ML	2026-03-18
HEPARIN SODIUM 10,000 UNIT/ML VIAL	71288-0404-02	2.28958	ML	2026-02-18
HEPARIN SODIUM 10,000 UNIT/ML VIAL	71288-0404-02	2.26180	ML	2026-01-21
HEPARIN SODIUM 10,000 UNIT/ML VIAL	71288-0404-02	2.24441	ML	2025-12-17
HEPARIN SODIUM 10,000 UNIT/ML VIAL	71288-0404-02	2.27743	ML	2025-11-19

Best Wholesale Price for NDC 71288-0404

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 71288-0404

Last updated: February 15, 2026

Overview

NDC 71288-0404 is a biologic drug marketed under the name Viatris’ fulvestrant (Faslodex), indicated for hormone receptor-positive metastatic breast cancer. The drug features a 250 mg intramuscular injection. Its market position is driven by indications, competition, pricing strategies, and reimbursement policies.

Current Market Landscape

• Therapeutic Area: Hormone receptor-positive metastatic breast cancer.
• Market Players:
  • AstraZeneca’s Faslodex remains the dominant drug.
  • Biosimilars are entering the market, increasing competition, potentially reducing prices.
• Market Size:
  • The U.S. breast cancer therapeutic market was valued at approximately $3.4 billion in 2022.
  • Fulvestrant's sales represent a significant share, with annual sales of around $600 million in the U.S. and comparable figures globally.

Market Drivers

• Indication Expansion: Additional approvals for earlier lines of therapy could expand patient populations.
• Biosimilar Entry: Biosimilar versions could decrease prices by up to 30-50%, depending on market uptake.
• Regulatory Trends: Increased emphasis on pricing transparency and value-based reimbursement may influence net prices.

Pricing Trends and Projections

• Current Price (U.S.): The average wholesale price (AWP) for a 4 mL (250 mg) autoinjector is approximately $3,600, aligned with Faslodex’s average sales price.
• Historical Pricing:
  • Pre-2020: Stable at around $3,600 per dose.
  • Post-2020: Slight decline observed with biosimilar development.
• Anticipated Price Changes:
  • Short-term (1–2 years): Expect stability due to high brand loyalty and limited biosimilar penetration.
  • Medium-term (3–5 years): Potential price declines of 15-25%, driven by biosimilar market entry and payer negotiations.
  • Long-term (5+ years): Prices could plateau or decrease further to $2,500–$3,000, mirroring biosimilar adjustments in other markets like Europe.

Pricing Comparisons and Benchmarking

Drug / Biosimilar	Current Price (U.S., per dose)	Market Share (2022)	Notes
Faslodex (original)	~$3,600	100%	High brand loyalty
Biosimilar 1 (expected launch)	~$2,700–$3,000	Variably up to 20–30%	Pending FDA approval
Biosimilar 2	~$2,500–$2,800		Several biosimilars under development

Impacts of Policy and Market Dynamics

• Payer pressure and managed care preferences could accelerate price reductions.
• The introduction of biosimilars in the U.S. could occur within 1-3 years, depending on FDA approvals and payer negotiations.
• International markets, particularly Europe, have seen biosimilar adoption rates of up to 50% within five years of launch, driving average prices down globally.

Summary of Price Projection

Timeline	Price Expectation	Key Factors
2023–2024	Stable at ~$3,600	Limited biosimilar impact, high brand loyalty
2025–2027	Moderate decline to $3,000	Biosimilar approval, payer negotiations
2028+	Further decline to $2,500–$3,000	Biosimilar market share growth, policy measures

Key Takeaways

• NDC 71288-0404 (Faslodex) holds a substantial share of hormone receptor-positive metastatic breast cancer therapy, with stable pricing in the short term.
• Biosimilar entries are likely to exert downward pressure on prices, with a potential 20-30% reduction within 3 years.
• Global trends indicate biosimilar adoption will continue to influence U.S. prices over the next 5+ years.
• Market expansion, indication updates, and reimbursement factors remain critical to price behavior.
• The overall market remains robust, with growth driven by demographic factors and treatment guideline updates.

FAQs

1. When is a biosimilar for Faslodex expected to launch in the U.S.?
   Likely within 1–3 years, contingent on FDA approval and payer dynamics.

2. What factors could delay biosimilar market entry?
   Regulatory delays, patent litigations, or strategic market decisions by incumbent companies.

3. How does biosimilar pricing compare internationally?
   European biosimilars have faced price reductions of up to 50%, influencing global price trends.

4. Is Faslodex still competitively priced?
   Yes, given current market shares and high brand loyalty, but pressure is rising as biosimilars prepare to enter.

5. What is the outlook for Faslodex’s revenue growth?
   Moderate growth driven by indication expansion; price reductions are expected to offset volume increases over time.

References

1. IQVIA. (2022). US Oncology Report.
2. EvaluatePharma. (2022). World Breast Cancer Market Data.
3. FDA. (2022). Biosimilar Pathway Guidance.
4. SSR Health. (2022). Drug Pricing and Market Trends.
5. Bloomberg Industry Reports. (2022). Biosimilar Market Analysis.